Global

The article discusses the potential of glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) as novel therapeutic agents for neurodegenerative diseases (NDs) like Alzheimer's disease (AD) and Parkinson's disease (PD). GRA have shown promising effects in modulating neuroinflammation, oxidative stress, mitochondrial and autophagic functions, and protein misfolding in preclinical studies. Clinical trials have demonstrated that GRA like exenatide, liraglutide, and lixisenatide can improve motor deficits in PD and cognitive function in AD patients.

This study investigated the prevalence and impact of auditory agnosia for environmental sounds in individuals with Alzheimer’s disease (AD), finding that over half exhibited signs of this central auditory dysfunction along with a high rate of unrecognized peripheral hearing loss. Although these factors appeared independent and showed limited direct effect on measured quality of life, possibly due to sheltered living environments and lack of patient awareness, they jointly contribute to daily functional decline, highlighting the importance of early hearing assessment and intervention in AD management.

This study indicates neurofibrillary tangles(NFT) level detection in patients with extracranial carotid atherosclerotic disease (ECAD) could enable earlier identification of those at high risk for developing Alzheimer's and other dementias, sometimes decades before symptoms. As blood-based assays to quantify NFT's are more clinically available, this could guide more targeted prevention and early treatment strategies for patients.

This study finds that optimal placement of long-duration energy storage in renewable-heavy power systems depends on multiple interacting factors—such as generation, demand, storage, and transmission—and cannot be determined by any single metric, with siting decisions having system-wide effects.